Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen

Liya Hu1, Sue E. Crawford2, Rita Czako2, Nicolas W. Cortes–Penfield2, David F. Smith3, Jacques Le Pendu4,5,6, Mary K. Estes2 & B. V. Venkataram Prasad4,2

As with many other viruses, the initial cell attachment of rotaviruses, which are the major causative agent of infantile gastroenteritis, is mediated by interactions with specific cellular glycans1–4. The distally located VP8* domain of the rotavirus spike protein VP4 (ref. 5) mediates such interactions. The existing paradigm is that ‘sialidase-sensitive’ animal rotavirus strains bind to glycans with terminal sialic acid (Sia), whereas ‘sialidase-insensitive’ human rotavirus strains bind to glycans with internal Sia such as GM1 (ref. 3). Although the involvement of Sia in the animal strains is firmly supported by crystallographic studies3,6,7, it is not yet known how VP8* of human rotaviruses interacts with Sia and whether their cell attachment necessarily involves sialoglycans. Here we show that VP8* of a human rotavirus strain specifically recognizes A-type histo-blood group antigen (HBGA) using a glycan array screen comprised of 511 glycans, and that virus infectivity in HT-29 cells is abrogated by anti-A-type antibodies as well as significantly enhanced in Chinese hamster ovary cells genetically modified to express the A-type HBGA, providing a novel paradigm for initial cell attachment of human rotavirus. HBGAs are genetically determined glycoconjugates present in mucosal secretions, epithelia and on red blood cells8, and are recognized as susceptibility and cell attachment factors for gastric pathogens like Helicobacter pylori9 and noroviruses10. Our crystallographic studies show that the A-type HBGA binds to the human rotavirus VP8* at the same location as the Sia in the VP8* of animal rotavirus, and suggest how subtle changes within the same structural framework allow for such receptor switching. These results raise the possibility that host susceptibility to specific human rotavirus strains and pathogenesis are influenced by genetically controlled expression of different HBGAs among the world’s population.

Rotaviruses are classified on the basis of the neutralization specificity of the outer capsid proteins VP7 and VP4 into G (VP7) and P (VP4) genotypes following a dual nomenclature system similar to influenza viruses11. The crystallographic structures of VP8* from two sialidase-insensitive human strains, representing P[8] (Wa)11 and P[4] (DS1)12, from two sialidase-sensitive animal strains, representing P[3] (RRV)13 and P[7] (CRW-8)14, and the structures of two animal VP8* with bound Sia13,14,15 have been previously reported. NMR, cell-binding and neutralization assays showed that the sialidase-insensitive P[8] Wa strain binds to gangliosides such as GM1 using internal Sia15. These studies suggested that whereas the sialidase-sensitive strains recognize glycans with terminal Sia such as GD1a, the sialidase-insensitive rotavirus strains bind to gangliosides such as GM1 with an internal Sia moiety, and gave rise to the notion that Sia is the key determinant for host-cell recognition in rotaviruses. Our goal was to determine whether all sialidase-insensitive human rotavirus genotypes recognize gangliosides with an internal Sia moiety for initial cell attachment, or whether they recognize different glycans in a genotype-dependent manner. VP8* (amino acids 64–224), cloned from a human rotavirus strain (HAL1166) first isolated from a child in Finland16, was expressed in Escherichia coli, purified to homogeneity and crystallized for structural analysis. The sialidase-insensitive HAL1166 strain, phylogenetically and serologically belongs to G8P[14] genotype17. Although not as prevalent as the P[4] and P[8] genotypes, the P[14] genotypes are being increasingly documented by global rotavirus surveillance15–17, and P[14] human rotaviruses are thought to be able to jump from animal to human hosts18.

The structure of the HAL1166 VP8* determined to 1.5 Å resolution shows the characteristic galectin-like fold with two twisted β-sheets separated by a shallow cleft as observed in the VP8* structures from other rotavirus strains (Fig. 1a). The structure of P[14] VP8* superimposes well with all of the VP8* structures previously determined. One significant difference between these structures is in the width of the cleft separating the two twisted β-barrel sheets (Fig. 1b). In P[14] VP8*, it is narrower than the cleft in the VP8* of the other two human strains, similar to that in the VP8* of the animal strains. In the animal VP8* structures, Sia binds near the cleft (Fig. 1c). Although the cleft in the P[14] VP8* structure is of similar dimensions as in the animal VP8* structures, the structural features in this region of P[14] VP8* is not compatible with Sia binding. In addition to changes in the amino acid residues (Fig. 1d) and side-chain orientations, the positioning of the amino acid residues is slightly shifted in this region because of an insertion (amino acid 187). The side-chain of Y188 is oriented in such a way that it would cause steric hindrance to Sia binding (Fig. 1c). Furthermore, the P[14] VP8* structure with a narrower cleft and several amino acid changes (Fig. 1d) is not compatible with binding of GM1 as suggested, based on computer modelling, for VP8* of the other human strains with a wider cleft17.

These observations prompted us to undertake a high throughput screening of a glycan array comprised of 511 different glycans, including several glycans with terminal or internal Sia. Such screening, which has been used to identify cellular glycans for a variety of pathogens including bacterial toxins18, influenza viruses19 and polyomavirus20, unambiguously showed specific binding to glycans with a terminal GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAc sequence (Fuc, fucose; Gal, galactose; Glc, glucose; NAc, N-acetyl, which is a characteristic of A-type HBGA (Supplementary Table 1, Supplementary Figs 1 and 2). None of the sialylated glycans, with either internal or terminal Sia, showed significant binding (Supplementary Table 1, blue).

To understand the structural interactions between P[14] VP8* and A-type HBGA, we co-crystallized VP8* with tri- and tetrasaccharides that correspond to the terminal structure in the A-type HBGA. The structure of the complex, determined to a similar resolution of 1.5 Å as the unliganded structure, clearly showed density for the bound ligand...
Insertion at position 187 causes a localized change which makes the side-chain of Y188 clash with Sia when placed in the structure of P[14] VP8*. The residue numbering corresponds to HAL1166 VP8*. The key amino acid changes in this region between P[14] and RRV VP8* are indicated by black arrows. Noticeable is how Y188 in the P[14] VP8* structure causes steric hindrance if Sia were to bind in this region. Also noticeable is the change in side-chain orientation of the conserved R101.

d. Alignment of HAL1166 VP8* with other VP8* sequences from sialidase-sensitive animal (RRV, CRW-8) strains, and sialidase-insensitive human rotavirus (Wa and DS1) strains. The residues that interact with Sia in the animal VP8* as shown in c are indicated by red stars on the top of the sequence. Highly conserved (>80%), and moderately conserved (>60%) regions are coloured in dark and lighter grey, respectively. The mean root square deviation (r.m.s.d.) of the matching Cz atoms between the P[14] VP8* and other VP8* structures along with percentage of sequence identity are shown in the table on the right.

The remarkable overlap of the HBGA binding site in the P[14] VP8* with that of the Sia in the animal VP8* structure strongly suggests that A-type HBGA is a cell attachment factor for P[14] rotavirus strains. To examine the biologic relevance of HBGA binding to P[14] VP8*, virus infectivity assays were performed. Using intestinal HT29 cells isolated from a type A individual, dose-dependent abrogation of HAL1166 infectivity was observed, with a greater than 75% reduction at the highest concentration of anti-A-type HBGA antibody compared to an isotype control antibody (Fig. 3a, b). In contrast, this antibody did not inhibit the sialidase-sensitive SA11 rotavirus strain (Fig. 3a). To ascertain further the specificity of the HAL1166 to A-type HBGA, infectivity assays were performed using parental Chinese hamster ovary (CHO) cells, which do not express any HBGA, and genetically-engineered CHO cells expressing either A- or H-type HBGA. CHO cells expressing type A HBGA showed a large increase in infectivity with HAL1166, but not SA11, compared to parental CHO cells or those expressing type H alone (Fig. 3c). Similarly, low infectivity was observed in Caco-2 cells, isolated from a blood type O individual, compared to HT29 cells that express type A HBGA (data not shown).

Specificity to A-type HBGA was further confirmed by performing
Figure 2 | Structural analysis of P[14] VP8*–A-type HBGA interactions. a, The chemical structure of the A-type trisaccharide (above) and simulated annealing omit difference map (below), contoured at 3σ level, showing the binding of A-type trisaccharide to P[14] VP8*. Bound A-type trisaccharide (GalNAC, N-acetylgalactosamine; Gal, galactose; Fuc, fucose) is shown in a ball-and-stick representation (yellow) inside the map with its carbon atoms numbered following the standard convention. The nitrogen and the oxygen atoms in the trisaccharide are coloured in blue and red, respectively. b, Surface representation of the P[14] VP8* structure (grey) with the bound A-trisaccharide shown in stick representation (with the same colour scheme as in a). The acetamido group of GalNAC inserts into a well-defined pocket in the VP8* structure. The amino acid residues in the P[14] VP8* which participate in hydrogen bond and hydrophobic interactions with the trisaccharide are indicated in blue. c, Network of hydrogen bond interactions (dashed lines) between the VP8* residues (light blue) and A-type trisaccharide (coloured as in a). Participating water molecules are shown as small spheres (cyan). More detailed interactions between VP8* and the ligand are given in Supplementary Fig. 4. The terminal two saccharide moieties of the A-type tetrasaccharide (GalNACx1-3(Fucx1-2)Galβ1-4GlCNAC) also show similar interactions with the VP8* (Supplementary Fig. 3).

Figure 3 | HAL1166 rotavirus specifically recognizes A-type HBGA. a, Dose-dependent inhibition of HAL1166 infection in HT29 cells by anti-A-type antibody (Ab, white bars for HAL1166, and black bars for SA11). Isotype control IgG3 did not inhibit HAL1166 infectivity (grey bars). Error bars (also in Fig. 3c) represent standard deviation and the P values were determined by Student’s t-test, n = 3. *All concentrations of anti-A-type antibody reduced infectivity compared to control with P < 0.05. b, Representative immunofluorescence microscopy images of HT29 cells infected with HAL1166 rotavirus in the presence of 50 μg ml−1 of IgG3 (top) and anti-A-type antibody (bottom). c, Infectivity of SA11 P[1], HAL1166 P[14] and K8 P[9] rotavirus strains in the parental CHO cells (H+/A−), the single transfectant with the Fut2 enzyme (H+/A−), and the double transfectant with both Fut2 and A type histo-blood group glycosyltransferase (H+/A+). The fold difference in infectivity was determined compared to parental cells. For HAL1166 and K8 human rotaviruses, the increase in infectivity in CHO (A+/H+) cells was compared to parental CHO, and CHO (H+/A−), the P values were <0.01.

haemagglutination assays using P[14] glutathione-S-transferase (GST)–VP8*. Type A blood cells, but not type O or B, were haemagglutinated by soluble VP8* (Supplementary Fig. 5).

This is the first study describing the structural interactions between a human VP8* and a cellular glycan. Importantly, it shows that binding of sialylated glycans is not obligatory among sialidase-insensitive human rotavirus strains. Our finding that P[14] VP8* specifically recognizes HBGA raises important questions such as whether other human rotavirus strains interact with similar or other HBGAs in a serotype-dependent manner like in human noroviruses, and whether genetically controlled differential expression of HBGAs among world’s population plays a role in susceptibility to human rotaviruses. In a recently published paper, G8P[14] rotavirus was identified in the stool samples from two adults with diarrhoea, who lived in the same geographical area in Denmark. The blood type of one of these patients and of another patient infected with a G6P[14] virus was type A (B,
Böttiger, personal communication). Although this is a small sample size, these findings warrant further epidemiological studies to determine whether HBGA is a susceptibility factor for rotaviruses. Based on sequence comparisons, our prediction that VP8* of the K8 human rotavirus strain (P[9] genotype) would also recognize A-type HBGA (Supplementary Fig. 6) is firmly supported by infectivity assays with parental and derivative CHO cells (Fig. 3c).

The double-stranded RNA rotaviruses, accounting for approximately 500,000 child deaths annually worldwide22, have enormous genetic and strain diversity. In addition to point mutations and gene rearrangements, genetic reassortment between co-circulating strains, similar to influenza viruses, contribute to the expanding diversity of rotaviruses23,24. Current evidence indicates that many of the human rotavirus strains, including the P[14] HAL1166 strain27, originated from animal reservoirs through reassortment and inter-species transmission23,24. Although effective vaccines are currently available, whether they will remain effective with such expanding virus diversity is an open question25,26. Discovery that a human rotavirus strain with host-switching capabilities binds to a non-sialylated but novel glycan receptor opens new approaches to better understand the molecular basis of critical human rotavirus–host interactions, which probably influences host specificity, cell specificity, pathogenesis and virus evolution.

METHODS SUMMARY

Expression, purification, and crystallization of P[14] VP8* and its complex with A-type oligosaccharides, and structure determination, using RRV VP8* structure (PDB ID: 1KQR) as a molecular replacement model, and refinement was carried out as described in the Methods section. Diffraction data were collected at Baylor College of Medicine using a Rigaku FR-E+ SuperBright rotating anode. See Supplementary Table 2 for data collection and refinement statistics. The carbohydrate-binding specificity of P[14] VP8* was investigated using glycan array v4.2 with 511 glycans in replicates of six (Consortium for Functional Glycomics Protein–Glycan Interaction Core (H) (http://www.functionalglyc.com). GST-tagged VP8* bound on the glycan array was detected using a fluorescent-labelled anti-GST monoclonal antibody. Infectivity assays were performed as previously described27.

Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.

Received 21 June 2011; accepted 29 February 2012.

Published online 15 April 2012.

1. Blanchard, H., Yu, X., Coulson, B. S. & von Ittzez, M. Insight into host cell carbohydrate-recognition by human and porcine rotavirus from crystal structures of the virion spike associated carbohydrate-binding domain (VP8*). J. Mol. Biol. 367, 1215–1226 (2007).
2. Dormitzer, P. R. et al. Specificity and affinity of sialic acid binding by the rhesus rotavirus VP8* core. J. Virol. 76, 10512–10517 (2002).
3. Haselhorst, T. et al. Sialic acid dependence in rotavirus host cell invasion. Nature Chem. Biol. 5, 91–93 (2009).
4. Lopez, S. & Arias, C. F. Early steps in rotavirus cell entry. Curr. Top. Microbiol. Immunol. 309, 39–66 (2006).
5. Settembre, E. C., Chen, J. Z., Dormitzer, P. R., Grigorieff, N. & Harrison, S. C. Atomic model of an infectious rotavirus particle. EMBO J. 30, 408–416 (2011).
6. Dormitzer, P. R., Sun, Z. Y., Wagner, G. & Harrison, S. C. The rhesus rotavirus VP4 sialic acid binding domain has a galectin fold with a novel carbohydrate binding site. EMBO J. 21, 885–897 (2002).
7. Kraschnewski, M. J. et al. Effects on sialic acid recognition of amino acid mutations in the carbohydrate-binding cleft of the rotavirus spike protein. Glioboclysis 13, 194–200 (2009).
8. Marionneau, S. et al. ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie 83, 565–573 (2001).
9. Iver, D. et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 275, 373–377 (1997).
10. Glass, R. I., Parashar, U. D. & Estes, M. K. Norovirus gastroenteritis. N. Engl. J. Med. 361, 1776–1785 (2009).
11. Matthijssens, J. et al. Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch. Virol. 156, 1397–1413 (2011).
12. Monnier, N. et al. High-resolution molecular and antigen structure of the VP8* core of a sialic acid-independent human rotavirus strain. J. Virol. 80, 1513–1523 (2006).
13. Gerna, G. et al. Identification of a new VP4 serotype of human rotaviruses. Virology 200, 66–71 (1994).
14. Ciarlet, M. & Estes, M. K. Human and most animal rotavirus strains do not require the presence of sialic acid on the cell surface for efficient infectivity. J. Gen. Virol. 80, 943–948 (1999).
15. Chitambar, S. D., Arora, R., Kolpe, A. B., Yadav, M. M. & Raut, C. G. Molecular characterization of unusual bovine group A rotavirus G8P[14] strains identified in western India: emergence of P[14] genotype. Vet. Microbiol. 148, 384–388 (2011).
16. Fukai, K., Saito, T., Inoue, K. & Sato, M. Molecular characterization of novel P[14],G8 bovine group A rotavirus, Sun9, isolated in Japan. Virus Res. 105, 101–106 (2004).
17. Matthijssens, J. et al. Are human P[14] rotavirus strains the result of interspecies transmissions from sheep or other ungulates that belong to the mammalian order Artiodactyla? J. Virol. 83, 2917–2929 (2009).
18. Byres, E. et al. Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin. Nature 452, 648–652 (2008).
19. Stevens, J. et al. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J. Mol. Biol. 355, 1143–1155 (2006).
20. Neu, U. et al. Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe 8, 309–319 (2010).
21. Midgley, S. E., Huljsager, C. K., Larsen, L. E., Falkenhorst, G. & Böttiger, B. Suspected zoonotic transmission of rotavirus group A in Danish adults. Epidemiol. Infect. doi:10.1017/S0950268811001981 (27 September 2011).
22. Parashar, U. D., Gibson, C. J., Bresse, J. S. & Glass, R. I. Rotavirus and severe childhood diarrhea. Emerg. Infect. Dis. 12, 304–306 (2006).
23. Estes, M. K. & Kapikian, A. Z. in Fields Virology Vol. 2 (eds Knipe, D. M. & Howley, P. M.) 1917–1974 (Lippincott Williams & Wilkins, 2007).
24. Gray, J. & Ittmaza-Gomara, M. Rotaviruses. Methods Mol. Biol. 665, 325–355 (2011).
25. Angel, J., Franco, M. A. & Greenberg, H. B. Rotavirus vaccines: recent developments and future considerations. Nature Rev. Microbiol. 9, 529–539 (2009).
26. Gentisch, J. R. et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J. Infect. Dis. 192 (Suppl 1), S146–S159 (2005).
27. Guillot, P. et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology 18, 1085–1093 (2008).

Supplementary Information is linked to the online version of the paper at www.nature.com/nature.

Acknowledgements We acknowledge the support from NIH grants AI36040 (to B.V.V.P.), AI 080656 and P30 DK56338 (to M.K.E.), GM62116 (to the Consortium for Functional Glycomics), and the Robert Welch foundation (Q1279) to B.V.V.P. We thank R. Atmar and S. Shanker for helpful discussions and BCM X-ray core facility for data collection.

Author Contributions L.H. carried out expression, purification, crystallization, diffraction data collection and structure determination, L.H., S.E.C., R.C. and N.W.C.-P. contributed to virus infectivity assays in HT29, CHO cells and haemagglutination assays and data analyses. D.F.S. contributed to glycan array experiments and analysis. J.L.P., provided parental and genetically modified CHO cells and advice. M.K.E. provided supervision and advice on cell infectivity assays and analysis. L.H. and B.V.V.P. analysed and interpreted the structural data. B.V.V.P. contributed to the overall direction of the project and wrote the manuscript with input from other authors.

Author Information: The coordinates and structure factors for the P[14] VP8* structures are deposited in the Protein Data Bank under accession numbers 4DDR (apo), 4DRV (with A-type trisaccharide) and 4DS0 (with A-type tetrasaccharide). Raw glycan array data are available at http://www.functionalglyc.com/glycomics/public/selectedScreens.jsp. Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Readers are welcome to comment on the online version of this article at www.nature.com/nature. Correspondence and requests for materials should be addressed to B.V.V.P. (vprasad@bcm.edu).
METHODS
Protein expression and purification. VP8* (amino acids 64–224) of HALL166 rotavirus strain (P[14] genotype) was cloned into an expression vector pGEX-2T (GE healthcare) with an N-terminal GST tag and a thrombin cleavage site. The recombinant GST-VP8* was expressed in E. coli BL21 (DE3) (Novagen) and purified by Glutathione Sepharose 4 Fast Flow (GE healthcare). The GST tag was cleaved by using thrombin before re-binding the protein mixtures onto a Glutathione Sepharose column to remove the GST, leaving Gly-Ser at the N terminus. The VP8* was then filtered and further purified by size-exclusion chromatography on a Superdex-75 (GE healthcare) column with 10 mM Tris, pH 7.4, 100 mM NaCl, 1 mM diethiothreitol (DTT). The concentration of the purified VP8* was determined by measuring absorbance at 280 nm and using an absorption coefficient of 43,010 M⁻¹ cm⁻¹ calculated using Vector NTI 11 software (Invitrogen).

Crystallization. Crystallization conditions for P[14] VP8* (13.5 mg ml⁻¹) were screened by hanging-drop vapour diffusion using the Mosquito crystallization robot (TTP LabTech) and visualized using Rock Imager (Formulatrix) at 20 °C. The crystals from one of the conditions (30% PEG 1500, sodium acetate trihydrate, pH 4.5) were harvested with the screen condition containing 18% glycerol. To obtain crystals of VP8*-HBGA complex, VP8* was co-crystallized with A-type tri saccharide or tetrasaccharide (purchased from Dextra labs), with a 1.52 or 1.46 excess molar ratio of ligand under similar condition as the unliganded P[14] VP8*.

Data collection and processing. Diffraction data for both unliganded and liganded VP8* crystals were collected at Baylor College of Medicine using Rigaku FR-E+ SuperBright rotating anode. These data were processed with DREXII or IMOSFLM as implemented in the CCP4 suite. Space group was confirmed using POINTLESS. The unliganded and liganded VP8* structures in the P2₁ space group, with one molecule in the asymmetric unit, at 1.5 Å resolution were determined. For initial phasing, the RRV VP8* structure (PDB ID 1QKR) was used as a search model for molecular replacement using Phaser. Following automated model building and solvent addition using ARP/WARP, the structure was refined using PHENIX. The oligosaccharide moieties of the HBGAs were generated using the SWEET2 package of the Glycosciences.de server (http://www.glycosciences.de) and modelled into the electron density using COOT and validated by computing simulated annealing omit maps using POINTLESS. The stereochemistry of the oligosaccharides including the allowed conformational angles was checked using the CARP package in the Glycosciences.de server. Data collection and refinement statistics are given in Supplementary Table 2. Ligand interactions were analysed using COOT and LIGPLOT with donor to acceptor distances between 2.6 Å and 3.2 Å for hydrophobic interactions. The structural alignments and calculations of r.m.s.d. were carried out using PyMOL (http://www.pymol.org). Figures were prepared using Chimera.

Glycan array screening. The carbohydrate-binding specificity of HAL166 VP8* was investigated on glycan array v4.2 comprised of 511 glycans ( Consortium for Functional Glycomics, Protein-Glycan Interaction Core-H) (http://www.functionalglycomics.org). Recombinant GST-VP8* at decreasing concentrations in binding buffer (20 mM Tris-HCl pH 7.4, 150 mM sodium chloride, 2 mM calcium chloride, 2 mM magnesium chloride, 0.05% Tween 20, 1% BSA) was applied to separate glycan arrays, and bound protein was detected using a fluorescent-labelled anti-GST monoclonal antibody. Summary of the glycan array results is given in Supplementary Table 1. Concentration dependent binding at 20 µg ml⁻¹ and 2 µg ml⁻¹ is shown in Supplementary Fig. 1a, b, where the glycans are ranked according to their relative binding strengths (Supplementary Fig. 1c) as described previously.

Inhibition and infectivity assays. Inhibition assays were performed on HT29 (human intestinal epithelial) cells following previously described protocols. The monoclonal antibody (MAB) against blood group A antigen (BG-2) was purchased from Covance. The isotype control antibody (MG3-35) was purchased from Abcam. HAL166 virus was grown as previously described. The carbohydrate-binding specificity of HAL1166 VP8* was investigated on glycan array v4.2 comprised of 511 glycans ( Consortium for Functional Glycomics, Protein-Glycan Interaction Core-H) (http://www.functionalglycomics.org). Recombinant GST-tagged VP8* was serially diluted by using 50 µl of the prep (starting dilution of 10 nM) with an equal volume of the RBC suspensions. Recombinant norovirus virus-like particles (Norwalk virus, genogroup GI.1 and Houston virus, genogroup GI.4) were included as positive controls (5 µg ml⁻¹ and 10 µg ml⁻¹ starting dilutions, respectively) because they have well-characterized haemagglutination activity that is known to be mediated by interaction with histo-blood group antigens on the surface of the red blood cells. The reaction was allowed to proceed for one hour at 4 °C before results were recorded. The titer recorded was the highest dilution of sample that prevented the complete sedimentation of red blood cells to the bottom of the well as compared to the negative controls. A commercial glycan binding type antibody specific for the B antigen was purchased from Immunex and tested at a starting dilution of 1:100 as another positive control.

28. Pfugrath, J. W. The finer things in X-ray diffraction data collection. Acta Crystallogr. D 55, 1718–1725 (1999).
29. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 239–242 (2011).
30. Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D 62, 72–82 (2006).
31. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
32. Morris, R. J., Perrakis, A. & Lamzin, V. S. ARP/WARP and automatic interpretation of protein electron density maps. Methods Enzymol. 374, 229–244 (2003).
33. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 231–242 (2010).
34. Bohne, A., Lang, E. & von der Lieth, C. W. SWEET - WWW-based rapid 3D construction of oligo- and polysaccharides. Bioinformatics 15, 767–768 (1999).
35. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Macromolecular Structure Solution. Acta Crystallogr. D 60, 2132–2143 (2004).
36. Luetteke, T., Frank, M. & von der Lieth, C. W. Carbohydrate Structure Suite (CSS): analysis of carbohydrate 3D structures derived from the PDB. Nucleic Acids Res. 33, D242–D246 (2005).
37. Wallace, A. C., Laskowski, R. A. & Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8, 127–134 (1995).
38. Peterson, E. F. et al. UCSF Chimeera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
39. Smith, D. F., Song, K. & Cummings, R. D. Use of glycan microarrays to explore specificity of glycan-binding proteins. Methods Enzymol. 480, 417–444 (2010).
40. Haselhorst, T. et al. Sialic acid dependence in rotavirus host cell invasion. Nature Chem. Biol. 5, 91–99 (2009).
41. Crawford, S. E. et al. Rotavirus viremia and extraintestinal viral infection in the neonatal rat model. J. Virol. 80, 4820–4832 (2006).
42. Guillou, P. et al. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology 18, 1085–1093 (2008).
43. Huston, A. M., Atmar, R. L., Marcus, D. M. & Estes, M. K. Norwalk virus-like particle hemagglutination by binding to H histo-blood group antigens. J. Virol. 77, 405–415 (2003).